The development-stage pharma company started an important clinical trial.
News & Analysis: Cara Therapeutics
A traditional tobacco company takes a stake in Auxly, while heads roll at CannTrust Holdings.
The company will issue 5 million shares to raise capital for its Korsuva pipeline drug.
Great growth prospects and relatively modest risk levels make these biotech stocks really attractive.
Which one of these unconventional drugmakers can give your portfolio the biggest boost?
The chances of a positive future appear to be pretty good for this clinical-stage biotech.
Two biotechs that don't have approved drugs yet. One clear winner.
These stocks didn't tank like most cannabis stocks did last month. But can their momentum keep going?
A pivotal trial for the company's lead candidate was an unequivocal success.
Should you put your hard-earned money into these stocks? We detail the investment opportunities, risks, and regulations in the cannabis space.